Artiva Biotherapeutics (ARTV) Institutional Ownership $3.60 +0.16 (+4.65%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.44 -0.16 (-4.31%) As of 07/25/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Artiva Biotherapeutics (NASDAQ:ARTV)Number ofInstitutional Buyers(last 12 months)19TotalInstitutional Inflows(last 12 months)$179.75MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$1.05M Get ARTV Insider Trade Alerts Want to know when executives and insiders are buying or selling Artiva Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ARTV Institutional Buying and Selling by Quarter Artiva Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025venBio Partners LLC1,198,975$3.60M2.9%-21.1%4.921% 5/12/2025Nuveen LLC47,892$144K0.0%N/A0.197% 5/9/2025Charles Schwab Investment Management Inc.54,881$165K0.0%+26.1%0.225% 2/17/2025Deutsche Bank AG21,423$216K0.0%N/A0.088% 2/17/2025Bank of America Corp DE10,817$109K0.0%-39.3%0.045% 2/17/2025BNP Paribas Financial Markets9,879$100K0.0%+262.1%0.041% 2/14/2025Northern Trust Corp117,112$1.18M0.0%+3.8%0.482% 2/13/2025Barclays PLC24,161$244K0.0%+23.2%0.099% 2/13/2025Wells Fargo & Company MN8,616$87K0.0%+64.0%0.035% 2/12/2025Geode Capital Management LLC315,758$3.18M0.0%+2.2%1.300% Get the Latest News and Ratings for ARTV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/12/2025Norges Bank30,000$302K0.0%N/A0.124% 2/12/2025JPMorgan Chase & Co.37,619$379K0.0%+250.7%0.155% 2/6/2025Charles Schwab Investment Management Inc.43,526$439K0.0%+8.0%0.179% 1/30/2025Rhumbline Advisers12,879$130K0.0%-13.1%0.053% 1/24/2025China Universal Asset Management Co. Ltd.5,150$52K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.10,726$166K0.0%N/A0.044% 11/27/2024Franklin Resources Inc.520,301$7.44M0.0%N/A2.142% 11/19/2024Barclays PLC19,616$304K0.0%N/A0.081% 11/16/2024Geode Capital Management LLC308,930$4.77M0.0%N/A1.272% 11/15/2024Barclays PLC19,616$304K0.0%N/A0.081% 11/15/2024Wellington Management Group LLP194,108$2.91M0.0%N/A0.799% 11/15/2024State Street Corp86,559$1.34M0.0%N/A0.356% 11/15/2024Samsara BioCapital LLC291,666$4.51M0.9%N/A1.201% 11/15/2024RA Capital Management L.P.9,853,302$152.23M1.8%N/A40.565% 11/15/2024RTW Investments LP148,844$2.30M0.0%N/A0.613% 11/14/2024Acuta Capital Partners LLC44,000$680K0.6%N/A0.181% 11/14/2024MetLife Investment Management LLC8,733$135K0.0%N/A0.036% 11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011% 11/12/2024Charles Schwab Investment Management Inc.40,293$623K0.0%N/A0.166% (Data available from 1/1/2016 forward) ARTV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ARTV shares? During the previous two years, 22 institutional investors and hedge funds held shares of Artiva Biotherapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($152.23M), Franklin Resources Inc. ($7.44M), Samsara BioCapital LLC ($4.51M), venBio Partners LLC ($3.60M), Geode Capital Management LLC ($3.18M), Wellington Management Group LLP ($2.91M), and RTW Investments LP ($2.30M).Learn more on Artiva Biotherapeutics' institutional investors. Which institutional investors have been buying Artiva Biotherapeutics' stock? Of the 19 institutional investors that purchased Artiva Biotherapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($9.85M), Franklin Resources Inc. ($520.30K), Geode Capital Management LLC ($315.76K), Samsara BioCapital LLC ($291.67K), Wellington Management Group LLP ($194.11K), RTW Investments LP ($148.84K), and State Street Corp ($86.56K). How much institutional buying is happening at Artiva Biotherapeutics? Institutional investors have bought a total of 11,721,588 shares in the last 24 months. This purchase volume represents approximately $179.75M in transactions. Which of Artiva Biotherapeutics' major shareholders have been selling company stock? The following institutional investors have sold Artiva Biotherapeutics stock in the last 24 months: venBio Partners LLC ($321.00K), Bank of America Corp DE ($7.00K), and Rhumbline Advisers ($1.95K). How much institutional selling is happening at Artiva Biotherapeutics? Institutional investors have sold a total of 329,947 shares in the last 24 months. This volume of shares sold represents approximately $1.05M in transactions. Related Companies CRGX Major Shareholders ACIU Major Shareholders NMRA Major Shareholders FDMT Major Shareholders EPRX Major Shareholders VTYX Major Shareholders OGI Major Shareholders SLS Major Shareholders YMAB Major Shareholders ALMS Major Shareholders This page (NASDAQ:ARTV) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.